Krystal's topical gene therapy gains steam, prompting analyst group to boost sales projection
Fierce Pharma
NOVEMBER 6, 2023
At the start of its first-ever conference call to present its quarterly numbers, Krystal Biotech CEO Krish Krishnan was quick to point out that the company’s positive earnings for the third quarter | Krystal Biotech's launch of Vyjuvek, the world's first topical gene therapy, has been so promising that analysts with Evercore ISI increased (..)
Let's personalize your content